In our case, when more stable and active inhibitors are developed, we then plan to use them as targeting vector (molecule) in radioconjugates, that can be used as theranostic-like radiopharmaceuticals for the imaging and therapy of cancers that overexpress NRP-1. This evidence concerns the gene NRP1 and cancer.